Parabilis Medicines closes $770.5 million IPO and concurrent private placement

Parabilis Medicines Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Parabilis Medicines (Nasdaq: PBLS) closed its upsized IPO of 38,525,000 common shares at $20.00 per share, including full exercise of the underwriters’ option. Shares started trading on June 10, 2026.

The company also closed a concurrent $75 million private placement to Regeneron and reported over $1.2 billion raised in 2026, with all preferred stock and a $50 million SAFE converting into common stock.

Loading translation...

AI-generated analysis. Not financial advice.

Positive

IPO gross proceeds of $770.5 million before fees and expenses

Concurrent private placement adds approximately $75 million in proceeds

Underwriters’ overallotment option for 5,025,000 shares fully exercised

Over $1.2 billion raised in 2026 across financings and collaborations

All preferred stock and $50 million SAFE converted into common shares

Negative

Total of 38,525,000 new shares issued in the IPO

Additional 4,166,666 shares issued in the concurrent private placement

Market Reaction – PBLS

-3.33%$29.30

15m delay15 alerts

-3.33%Since News

$29.30Last Price

-$123MValuation Impact

$3.56BMarket Cap

0.3xRel. Volume

Following this news, PBLS has declined 3.33%, reflecting a moderate negative market reaction. Our momentum scanner has triggered 15 alerts so far, indicating notable trading interest and price volatility. The stock is currently trading at $29.30. This price movement has removed approximately $123M from the company's valuation.

IPO price$20.00 per shareInitial public offering price on Nasdaq Global Select Market

Concurrent placement shares4,166,666 sharesConcurrent private placement to Regeneron Pharmaceuticals, Inc.

Concurrent placement price$18.00 per sharePrice in concurrent private placement (90% of IPO price)

IPO gross proceeds$770.5 millionGross proceeds from IPO before fees and expenses

Private placement proceedsapproximately $75 millionProceeds from concurrent private placement

2026 funding raisedover $1.2 billionTotal funding in 2026 across financings and collaborations

Market Reality Check

Price:$31.60Vol:Volume 5,482,901 is rough...

normal vol

$31.60Last Close

VolumeVolume 5,482,901 is roughly in line with the 20-day average of 5,487,568 ahead of/around the IPO news.normal

TechnicalTrading close to its 200-day moving average at 31.6, with price positioned below that trend level.

Market Pulse Summary

This announcement highlights the completion of an upsized IPO and concurrent private placement, brin...

Analysis

This announcement highlights the completion of an upsized IPO and concurrent private placement, bringing in IPO gross proceeds of $770.5 million plus approximately $75 million, and contributing to over $1.2 billion raised in 2026. Investors may track how this expanded capital base supports clinical development, how the post-IPO trading range develops relative to the $20.00 IPO price, and any follow-on disclosures about pipeline progress or capital allocation.

Key Terms

initial public offering, overallotment option, concurrent private placement, registration statements, +3 more

7 terms

initial public offeringfinancial

"announced the closing of its upsized initial public offering of an aggregate"

An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.

overallotment optionfinancial

"including the full exercise by the underwriters of their overallotment option"

An overallotment option (often called a "greenshoe") is a pre-arranged allowance for underwriters to sell or buy up to a specified extra percentage of a company’s shares during an offering to meet unexpected demand or support the share price. Think of it as a short-term buffer: it helps reduce wild swings right after shares start trading but can slightly increase the total shares outstanding if the option is exercised, which matters to investors because it affects supply, price stability, and potential dilution.

concurrent private placementfinancial

"in a concurrent private placement to Regeneron Pharmaceuticals, Inc."

A concurrent private placement is a sale of a company’s shares or bonds directly to a select group of investors that happens at the same time as another financing action or offering. Think of it as quietly selling a block of tickets to a few people while a larger ticket drive is underway; it raises cash quickly but can change ownership proportions, dilute existing shareholders and affect share price, so investors watch it as a sign of funding needs and potential value shifts.

registration statementsregulatory

"Registration statements relating to the initial public offering have been filed"

Registration statements are detailed documents companies file with securities regulators when they plan to offer shares or other securities to the public. They act like a recipe and instruction manual, listing a company’s business, finances, management, risks and how the offering will work, so investors can judge value and potential downsides. For investors, these filings provide the official, legally required facts needed to make informed decisions and spot warning signs.

prospectusregulatory

"The offering was made only by means of a prospectus forming part of the effective"

A prospectus is a detailed document that explains a company's plans for offering new shares or investments to the public. It’s important because it provides potential investors with key information about the company’s business, risks, and how they might make money, helping them decide whether to invest. Think of it as a guidebook for understanding what you're buying into.

Nasdaq Global Select Markettechnical

"Parabilis’ common stock began trading on the Nasdaq Global Select Market"

A Nasdaq Global Select Market listing is the highest tier of stocks on the Nasdaq exchange, reserved for companies that meet the strictest financial, reporting and governance standards. For investors, it acts like a premium quality label—signaling larger, more transparent and better-governed companies that tend to offer greater liquidity and lower perceived risk compared with lower-tier listings, making it easier to buy, sell and evaluate shares.

Simple Agreement for Future Equityfinancial

"and a $50 million Simple Agreement for Future Equity (“SAFE”) held by"

A simple agreement for future equity is an investment contract that gives an investor the right to receive company shares at a later financing event or sale instead of getting shares immediately. Think of it like a voucher that converts into ownership once the company’s value is formally set; it matters to investors because it fixes how and when ownership is awarded, affects how much of the company they ultimately own, and influences dilution and return potential.

AI-generated analysis. Not financial advice.

See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google

CAMBRIDGE, Mass., June 11, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines, Inc. (Nasdaq: PBLS) (“Parabilis”), a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease, today announced the closing of its upsized initial public offering of an aggregate 38,525,000 shares of its common stock, including the full exercise by the underwriters of their overallotment option to purchase 5,025,000 additional shares, at an initial public offering price of $20.00 per share. All of the shares of common stock were offered by Parabilis. Parabilis’ common stock began trading on the Nasdaq Global Select Market on June 10, 2026 under the ticker symbol “PBLS”.

Leerink Partners, BofA Securities, Evercore ISI and Guggenheim Securities acted as active book-running managers for the offering. LifeSci Capital acted as a passive bookrunning manager for the offering.

In addition to the shares sold in the initial public offering, Parabilis today announced the closing on June 11, 2026, of its sale of 4,166,666 shares of common stock at $18.00 per share, or 90% of the initial public offering price per share, in a concurrent private placement to Regeneron Pharmaceuticals, Inc. The sale of the shares of common stock in the concurrent private placement was not registered under the Securities Act of 1933, as amended.

The gross proceeds to Parabilis from the initial public offering, including full exercise of the underwriters’ option to purchase additional shares, before deducting underwriting discounts and commissions, and offering expenses payable by Parabilis, were $770.5 million. In addition, Parabilis received proceeds of approximately $75 million from the sale of shares of common stock in the concurrent private placement. All of the shares of common stock were offered by Parabilis.

In connection with the initial public offering, all Parabilis preferred stock converted into common stock, and a $50 million Simple Agreement for Future Equity (“SAFE”) held by Explore Investments LLC converted into common stock.

Parabilis has raised over $1.2 billion in funding (before fees and expenses) in 2026, across public and private financings and strategic collaborations, to support its mission to create extraordinary medicines for patients.

Registration statements relating to the initial public offering have been filed with the Securities and Exchange Commission (the “SEC”) and became effective on June 9, 2026. The offering was made only by means of a prospectus forming part of the effective registration statement relating to these shares. Copies of the final prospectus may be obtained from the SEC’s website at www.sec.gov or from: Leerink Partners LLC, Attn: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, telephone: 1-800-808-7525, email: [email protected]; BofA Securities, Inc., Attn: Prospectus Department, 201 North Tryon Street, Charlotte, NC 28255-0001, email: [email protected]; Evercore Group L.L.C., Attn: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, New York 10055, telephone: (888) 474-0200, email: [email protected]; or Guggenheim Securities, LLC, Attn: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, New York 10017, telephone: (212) 518-9544, email: [email protected].

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

AboutParabilis

Parabilis is a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease. Parabilis leverages its proprietary platform to pioneer a novel therapeutic modality, Helicons™, which are stabilized helical peptides engineered to bind and precisely modulate proteins that have long been beyond the reach of conventional medicines.

Contacts:

Media Contact: Jessica Freifeld [email protected]

Investor Contact: Tom Kotarakos [email protected]

FAQ

How much did Parabilis Medicines (PBLS) raise in its June 2026 IPO?

Parabilis Medicines raised gross proceeds of $770.5 million from its June 2026 IPO. According to Parabilis, this came from selling 38,525,000 common shares at $20.00 each, including full exercise of the underwriters’ option, before fees and expenses.

What are the details of the Parabilis Medicines (PBLS) concurrent private placement with Regeneron?

Parabilis completed a concurrent private placement to Regeneron worth approximately $75 million. According to Parabilis, it sold 4,166,666 common shares at $18.00 per share, equal to 90% of the IPO price, closing on June 11, 2026.

When did Parabilis Medicines (PBLS) start trading on Nasdaq and under what symbol?

Parabilis Medicines common stock began trading on the Nasdaq Global Select Market on June 10, 2026. According to Parabilis, the shares trade under the ticker symbol "PBLS", following the company’s upsized initial public offering of common stock.

How many shares were included in the Parabilis Medicines (PBLS) upsized IPO?

The Parabilis upsized IPO included 38,525,000 common shares in total. According to Parabilis, this figure includes the underwriters’ full exercise of their option to purchase 5,025,000 additional shares at the IPO price of $20.00 per share.

What happened to Parabilis Medicines preferred stock and SAFE at the time of the IPO?

All Parabilis preferred stock and a $50 million SAFE converted into common stock in connection with the IPO. According to Parabilis, the SAFE was held by Explore Investments and converted alongside preferred shares, simplifying the company’s capital structure.

How much total funding has Parabilis Medicines (PBLS) raised in 2026?

Parabilis reports raising over $1.2 billion in 2026 before fees and expenses. According to Parabilis, this total includes its IPO, the concurrent Regeneron private placement, other public and private financings, and strategic collaborations to support development of its medicines.

Source: Investing.com Forex